RxDoctor Payments Data

Emily Archbald, MD

Dermatology · Oklahoma City, OKNPI 1366647026

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 500 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations.

$8,457in general payments, 2019–2025

Across 500 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AbbVie$1K
  • Pfizer$1K
  • Sanofi$778
  • E.r. Squibb & Sons, L.L.C.$668
  • Johnson & Johnson$602
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$8,31698%
  • Education$1412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,457 in reported general payments places this provider in the 75th percentile of 114 dermatology providers in Oklahoma.

See all dermatology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$264,076
Medicare patients
993
Services billed
4,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab56$219,761
AdbryTralokinumab-Ldrm27$102,278
Taltz AutoinjectorIxekizumab13$87,162
Humira(Cf) PenAdalimumab12$77,364
Clobetasol Propionate87$4,783
Ketoconazole193$2,588
Doxycycline Hyclate55$2,156
Fluocinolone AcetonideFluocinolone/Shower Cap20$1,409
Minoxidil148$1,395
Finasteride125$1,375
Minocycline Hcl43$1,294
Tretinoin12$1,294
Clindamycin Phosphate41$1,153
Betamethasone Dipropionate22$955
Spironolactone49$783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
LEO Pharma Inc.Adbry$167$102,27827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 114 dermatology providers in Oklahoma.

Other dermatology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →